| US3262977A
              (en)
            
            * | 1962-03-10 | 1966-07-26 | Chinoin Gyogyszer Es Vegyeszet | N-aralkyl-1, 1-diphenyl-propylamine derivatives | 
        
          | NL296693A
              (en:Method)
            
            * | 1962-08-16 |  |  |  | 
        
          | DK111894A
              (en:Method) | 1962-11-15 |  |  |  | 
        
          | FR95908E
              (fr)
            
            * | 1963-11-09 | 1972-01-31 | Degussa | Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants. | 
        
          | DE1231704B
              (de) | 1963-12-19 | 1967-01-05 | Josef Klosa Dipl Chem Dr Rer N | Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen | 
        
          | US3457354A
              (en)
            
            * | 1965-09-21 | 1969-07-22 | Merck & Co Inc | Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives | 
        
          | US3895057A
              (en)
            
            * | 1967-10-13 | 1975-07-15 | Dainippon Pharmaceutical Co | Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof | 
        
          | US4329367A
              (en)
            
            * | 1974-08-05 | 1982-05-11 | Ciba-Geigy Corporation | 1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes | 
        
          | DE2902172C2
              (de)
            
            * | 1979-01-20 | 1984-05-10 | UOP Inc., 60016 Des Plaines, Ill. | Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins | 
        
          | JPS59500764A
              (ja)
            
            * | 1982-04-23 | 1984-05-04 | カオラ コズメテイカイ エス ハズタルタスベジパリ バララト | プレニルアミン含有化粧品組成物 | 
        
          | NZ215753A
              (en)
            
            * | 1985-04-16 | 1989-10-27 | Hoffmann La Roche | Phenethanolamine derivatives and pharmaceutical compositions | 
        
          | US6982251B2
              (en)
            
            * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents | 
        
          | EP1671650A1
              (en)
            
            * | 2001-01-26 | 2006-06-21 | Schering Corporation | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | 
        
          | AU2002237927B2
              (en)
            
            * | 2001-01-26 | 2005-04-21 | Schering Corporation | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | 
        
          | AR035739A1
              (es)
            
            * | 2001-01-26 | 2004-07-07 | Schering Corp | Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares | 
        
          | ES2286233T3
              (es)
            
            * | 2001-01-26 | 2007-12-01 | Schering Corporation | Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares. | 
        
          | ATE348649T1
              (de)
            
            * | 2001-01-26 | 2007-01-15 | Schering Corp | Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen | 
        
          | US7071181B2
              (en)
            
            * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors | 
        
          | PL205343B1
              (pl)
            
            * | 2001-01-26 | 2010-04-30 | Schering Corp | Zastosowanie inhibitora wchłaniania sterolu | 
        
          | AU2002308778A1
              (en)
            
            * | 2001-05-25 | 2002-12-09 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease | 
        
          | EP1427409B1
              (en)
            
            * | 2001-09-21 | 2008-10-15 | Schering Corporation | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | 
        
          | US7056906B2
              (en)
            
            * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | 
        
          | CA2460340C
              (en)
            
            * | 2001-09-21 | 2011-02-15 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors | 
        
          | US7053080B2
              (en)
            
            * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | 
        
          | US20030119808A1
              (en)
            
            * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects | 
        
          | EP1545519B1
              (en) | 2002-08-19 | 2011-03-23 | Pfizer Inc. | Combination therapy for hyperproliferative diseases | 
        
          | CA2504878A1
              (en)
            
            * | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination | 
        
          | ES2311806T3
              (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. | 
        
          | ES2318274T3
              (es) | 2003-03-07 | 2009-05-01 | Schering Corporation | Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia. | 
        
          | US7192944B2
              (en)
            
            * | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | 
        
          | US7459442B2
              (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | 
        
          | JP2007510659A
              (ja)
            
            * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 | 
        
          | AU2005269465A1
              (en)
            
            * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | 
        
          | US20060063803A1
              (en)
            
            * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | 
        
          | US7741317B2
              (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators | 
        
          | EP2351569B1
              (en) | 2005-10-26 | 2012-08-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension | 
        
          | EP1951253A2
              (en) | 2005-10-26 | 2008-08-06 | Cotherix, Inc. | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension | 
        
          | US7888376B2
              (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors | 
        
          | US7919506B2
              (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives | 
        
          | EP2094643B1
              (en) | 2006-12-01 | 2012-02-29 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases | 
        
          | CA2688161C
              (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | 
        
          | US8969514B2
              (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 
        
          | US20100120694A1
              (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | 
        
          | ES2624828T3
              (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros | 
        
          | US9616097B2
              (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use | 
        
          | US8883844B2
              (en) | 2010-09-24 | 2014-11-11 | Nitrogenix Inc. | Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions | 
        
          | WO2014151200A2
              (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders | 
        
          | EP2970384A1
              (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses | 
        
          | CN105143203A
              (zh) | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物 | 
        
          | AU2014274812B2
              (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same | 
        
          | WO2016055901A1
              (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds | 
        
          | ES3007652T3
              (en) | 2019-01-18 | 2025-03-20 | Astrazeneca Ab | 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof |